ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 151 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $3,090,000 | -77.7% | 43,414 | -76.6% | 0.08% | -73.0% |
Q4 2021 | $13,865,000 | +33.5% | 185,411 | +1.4% | 0.28% | +44.7% |
Q3 2021 | $10,386,000 | +18.0% | 182,816 | -8.6% | 0.20% | +20.1% |
Q2 2021 | $8,801,000 | -7.7% | 199,970 | +3.4% | 0.16% | -18.8% |
Q1 2021 | $9,539,000 | -1.9% | 193,416 | -16.3% | 0.20% | -7.3% |
Q4 2020 | $9,728,000 | +12.9% | 231,071 | +22.8% | 0.22% | -25.3% |
Q3 2020 | $8,614,000 | -16.5% | 188,164 | -8.4% | 0.29% | -21.7% |
Q2 2020 | $10,313,000 | +35.0% | 205,400 | +38.2% | 0.37% | -9.5% |
Q1 2020 | $7,642,000 | -17.1% | 148,600 | -0.5% | 0.41% | -2.8% |
Q4 2019 | $9,223,000 | +3.3% | 149,293 | +0.5% | 0.42% | -13.6% |
Q3 2019 | $8,928,000 | -26.4% | 148,604 | +3.3% | 0.49% | -18.2% |
Q2 2019 | $12,134,000 | -16.1% | 143,799 | -5.0% | 0.60% | -22.7% |
Q1 2019 | $14,454,000 | +34.2% | 151,322 | -0.5% | 0.78% | +1.7% |
Q4 2018 | $10,767,000 | +21.9% | 152,007 | +47.1% | 0.76% | +59.3% |
Q3 2018 | $8,830,000 | -24.3% | 103,320 | +2.6% | 0.48% | -31.9% |
Q2 2018 | $11,668,000 | +55.2% | 100,670 | +8.4% | 0.70% | +29.5% |
Q1 2018 | $7,517,000 | +42.6% | 92,907 | +3.4% | 0.54% | +30.8% |
Q4 2017 | $5,270,000 | +10.3% | 89,811 | -12.0% | 0.42% | +4.3% |
Q3 2017 | $4,776,000 | -12.5% | 102,041 | -32.7% | 0.40% | -20.9% |
Q2 2017 | $5,458,000 | -10.2% | 151,695 | -23.2% | 0.50% | -17.5% |
Q1 2017 | $6,080,000 | -63.4% | 197,408 | -60.2% | 0.61% | +6.8% |
Q4 2016 | $16,617,000 | +32.5% | 496,025 | +5.3% | 0.57% | +38.9% |
Q3 2016 | $12,537,000 | +37.5% | 471,135 | +14.0% | 0.41% | +23.8% |
Q2 2016 | $9,116,000 | -25.5% | 413,415 | -0.7% | 0.33% | -25.4% |
Q1 2016 | $12,230,000 | +4.9% | 416,425 | +18.0% | 0.44% | +11.0% |
Q4 2015 | $11,657,000 | -20.0% | 353,025 | -12.5% | 0.40% | -11.1% |
Q3 2015 | $14,580,000 | +37.8% | 403,430 | +71.6% | 0.45% | +50.8% |
Q2 2015 | $10,578,000 | – | 235,130 | – | 0.30% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |